ライフサイエンスコーパス: gene delivery

1 t may become a novel nonviral nanosystem for gene delivery.

2 rge number of mice following therapeutic AAV gene delivery.

3 s for developing new approaches for targeted gene delivery.

4 to the trans-Golgi network is necessary for gene delivery.

5 be tuned for improved localized intratumoral gene delivery.

6 nslational block" occurring after Ad.5-mda-7 gene delivery.

7 of the most efficient non-viral systems for gene delivery.

8 present a promising alternative approach for gene delivery.

9 molecular weight PEI (1.8 kDa) for efficient gene delivery.

10 ne of the most critical steps for successful gene delivery.

11 sponsive SELPs for localized matrix-mediated gene delivery.

12 Dawley rats by using lentiviral vector-based gene delivery.

13 he LPDS-nanoplexes showed a greatly improved gene delivery.

14 rapy of metastatic cancer after MSC-mediated gene delivery.

15 ock when used in combination with adenoviral gene delivery.

16 s posttreatment compared to traditional rAAV gene delivery.

17 t have led to exciting advances in non-viral gene delivery.

18 NPs, and shed light on the NP-based drug and gene delivery.

19 tors for determining HCC incidence after AAV gene delivery.

20 ic biology, assisted fertilization, and drug/gene delivery.

21 is a critical aspect influencing successful gene delivery.

22 study the application of NPs to therapeutic gene delivery.

23 exposure should lead to increased levels of gene delivery.

24 te a hydrodynamic effect as the mechanism of gene delivery.

25 site, namely the nucleus for the purposes of gene delivery.

26 in vivo and may prove useful for therapeutic gene delivery.

27 apabilities to further the field of drug and gene delivery.

28 licable to achieve intracellular protein and gene delivery.

29 s, as well as emerging cationic polymers for gene delivery.

30 sing non-viral method for safe and selective gene delivery.

31 mbic brain regions that we targeted by viral gene delivery.

32 ssociated virus (AAV), a parvovirus used for gene delivery.

33 nsights into overcoming cellular barriers to gene delivery.

34 haracteristics that can be applied to spinal gene delivery.

35 tify unprecedented capabilities in non-viral gene delivery.

36 lkyl side chains are developed for non-viral gene delivery.

37 fere with the efficacy of viral vector-based gene delivery.

38 t ventricular (LV) remodeling after systemic gene delivery.

39 d to the EC surface marker CD105 for in vivo gene delivery.

40 gnificantly increase cytoplasmic and nuclear gene delivery.

41 using adeno-associated virus (AAV)-mediated gene delivery.

42 acy and safety were evaluated 2 months after gene delivery.

43 gy is to use organic nanoparticles (NPs) for gene delivery.

44 y terminate AT in atria light-sensitized via gene delivery.

45 nal design of nonviral vectors for efficient gene delivery.

46 ted channelrhodopsin-2 (ChR2) expression via gene delivery.

47 th nucleic acids to form lipoplexes used for gene delivery.

48 peutic efficacy was evaluated 2 months after gene delivery.

49 luronic acid (LPH) nanoparticle for systemic gene delivery.

50 espan of the Npc1-/- mice after systemic AAV gene delivery.

51 s associated with using nonviral vectors for gene delivery.

52 ine if they increased adeno-associated virus gene delivery.

53 tudied as a promising tool for intracellular gene delivery.

54 are several practical barriers to successful gene delivery.

55 eat significance in order to achieve optimal gene delivery.

56 t atrial ejection fraction at 2 months after gene delivery (-4.3 +/- 3.1% vs. 7.5 +/- 3.1%; p = 0.02)

57 ility of the AAV9 vector to mediate systemic gene delivery after intravenous administration to perina

58 The design of hybrid gene delivery agents comprising both virally derived and

59 nalized magnetic nanoparticle (MNP)-mediated gene delivery also resulted in sustained gene expression

60 hy genetics, coupled with recent advances in gene delivery and endogenous gene and transcript repair

61 n with FUS-BBB opening can provide effective gene delivery and expression in the CNS, demonstrating t

62 tors represent an alternative technology for gene delivery and expression with a potential to overcom

63 Recent technological advances in gene delivery and expression, nanoparticles, protein man

64 systems represent the bottom-up approach to gene delivery and gene silencing, in which scientists ar

65 ors are useful experimental tools for stable gene delivery and have been used to treat human inherite

66 ure on zein as a biopolymer for drug/vaccine/gene delivery and its applicability in tissue engineerin

67 elivery system for receptor-mediated drug or gene delivery and novel therapy for rheumatoid arthritis

68 ases, but they are better known as tools for gene delivery and oncolytic anticancer therapy.

69 neonatal rat cardiomyocytes with adenoviral gene delivery and pharmacological inhibitors, we found t

70 paradigms in combination with viral-mediated gene delivery and pharmacology.

71 te that these conditions result in efficient gene delivery and prolonged gene expression (up to 21day

72 binant retroviruses provide highly efficient gene delivery and the potential for sustained gene expre

73 dical applications such as targeted drug and gene delivery and theranostics.

74 emic nature and challenges including in vivo gene delivery and transient gene expression.

75 We identified several kinases that influence gene delivery and/or expression by performing a kinome-l

76 hy (CT) and magnetic resonance (MR) imaging, gene-delivery and photothermal therapy.

77 YSNs including biosensing, bioimaging, drug/gene delivery, and cancer therapy are discussed in detai

78 eno-associated viral vectors for therapeutic gene delivery applicable to the treatment of diverse dis

79 uitable for colloidal science as well as for gene delivery applications.

80 s represent a new and promising nonviral DNA/gene delivery approach endowing immunomodulatory propert

81 We explored a gene delivery approach for JNCL by generating two self-c

82 s the efficacy of non-viral TUS-based hSef-b gene delivery approach for the treatment of prostate can

83 roporation as a safe and effective non-viral gene delivery approach needed in many biological researc

84 We explored a gene delivery approach using two self-complementary aden

85 SIRT1 levels in MJD mouse model, through the gene delivery approach, significantly ameliorates neurop

86 ctroporation serves as a promising non-viral gene delivery approach, while its current configuration

87 ), Mef2c (M), and Tbx5 (T) using the current gene delivery approach.

88 n the PFC (postsynaptic site), using a viral gene-delivery approach, rescued the otherwise absent pot

89 gene transfer vectors and transient nonviral gene delivery approaches that are prevalent in ongoing c

90 Polymeric vectors for gene delivery are a promising alternative for clinical a

91 hancer/promoter selection, and the timing of gene delivery are all critical factors for determining H

92 iated virus (AAV) vectors are attractive for gene delivery-based therapeutics, but data from recent c

93 s and tools, resulting in increased in vitro gene delivery beyond individual vector components or com

94 hotodynamic therapy, radiation therapy, drug/gene delivery, biosensing, and bioimaging.

95 ble of overcoming the biological barriers to gene delivery both in vitro and in vivo.

96 r clinical trials, which currently use viral gene delivery, but focus primarily on new advancements i

97 vehicle screening was demonstrated using GFP gene delivery by different formulations of nanopolymers.

98 s suggest a set of new design principles for gene delivery by the synergistic co-assembly of mRNA wit

99 oups of drugs enhance adeno-associated virus gene delivery by unknown mechanisms.

100 anufacturing combined with scaffold-mediated gene delivery can be used to tissue engineer large anato

101 strates that a single intrathecal lentiviral gene delivery can lead to Schwann cell-specific expressi

102 gered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug t

103 en incorporated into materials for non-viral gene delivery, cancer therapy or treatment of microbial

104 s been intensely exploited for drug release, gene delivery, cancer thermotherapy, and energy harvesti

105 his liposome-like vesicle may be a promising gene delivery carrier for intravenous therapy.

106 tro with an aim of developing more efficient gene delivery carriers.

107 reprogramming and crucial steps involved in gene delivery, cell adhesion and culturing conditions th

108 sed, including nanopatterning, targeted drug/gene delivery, cell manipulation, and precision nanosurg

109 ts of CpG motif reduction in lentiviral (LV) gene delivery context on the level and duration of repor

110 The annual market value for successful gene delivery could exceed US$30 billion, and this will

111 Our results have demonstrated that bpoz-2 gene delivery could have prospect in the amelioration of

112 ing for disease diagnosis, targeted drug and gene delivery, directed stem cell differentiation, accel

113 ble their broad applications in the field of gene delivery, drug delivery, bio-imaging, tissue engine

114 gene delivery is developed and showing high gene delivery efficacy with low cytotoxicity.

115 study the effect of polymer architecture on gene delivery efficiency and cell cytotoxicity, a set of

116 Next, rAAV-mediated miR-208a gene delivery enhanced heart contractility and relaxatio

117 We discuss options for gene delivery experiments to test circuit and behavioral

118 by vascular endothelial growth factor (VEGF) gene delivery failed to show efficacy.

119 ents in optimizing the efficacy of non-viral gene delivery for ocular diseases.

120 concept for an approach using liver-targeted gene delivery for tolerance induction to donor antigen.

121 e regeneration and could potentially improve gene delivery for treating muscular dystrophies.

122 tential to achieve non-invasive and targeted gene delivery for treatment of CNS diseases.

123 te-of-the-art commercially available in vivo gene delivery formulation, i.v. delivery of the core/PEG

124 Ultrasound (US)-mediated gene delivery has emerged as a promising non-viral metho

125 Localized gene delivery has many potential clinical applications.

126 ng developed as vectors for corrective human gene delivery have shown promise in clinical trials, but

127 ies have found these vesicles are capable of gene delivery, however the consequences of vesicle-media

128 and cellular scales for new applications in gene delivery immunotherapy.

129 Moreover, BDNF gene delivery improved synaptophysin immunoreactivity in

130 AC domain in GP64 and its role in modulating gene delivery in AcMNPV.

131 NGF) gene therapy in AD, the first effort at gene delivery in an adult neurodegenerative disorder.

132 some-mimics (EMs) in sufficient quantity for gene delivery in cancer both in vitro and in vivo.

133 o achieve effective intracellular protein or gene delivery in clinical practice.

134 uses (Ads) have shown promise as vectors for gene delivery in clinical trials.

135 of this in vitro study is to evaluate PDGF-B gene delivery in fibroblasts using nano-sized calcium ph

136 ted hepatocellular carcinoma (HCC) after AAV gene delivery in mice.

137 ently being advocated for increasing drug or gene delivery in neurological diseases.

138 nfirms that AAV9 can safely mediate systemic gene delivery in small and large animal models and suppo

139 the key to engineering optimal polymers for gene delivery in the future.

140 c or adeno-associated virus-mediated TNFAIP3 gene delivery in the liver in both mouse and nonhuman pr

141 iew, we introduce the biological barriers to gene delivery in vivo and discuss recent advances in mat

142 achieve temporary transgene repression after gene delivery in vivo, we utilized a nonintegrating vers

143 te exchange, or RMCE, is a clean approach of gene delivery into a desired chromosomal location, as it

144 d lentiviral vectors (LVs) enabling specific gene delivery into endothelial cells in vivo.

145 us infection as well as be used as tools for gene delivery into epithelial tissues or epithelial tumo

146 Gene delivery into hCD34+ hematopoietic stem/progenitor

147 PP transgenic mice underwent lentiviral BDNF gene delivery into the entorhinal cortices at age 2 mont

148 Thus, ultrasound mediated gene delivery is a promising technique for the clinical

149 Gene delivery is a promising way to treat hereditary dis

150 carrier for dual-stimuli triggered cytosolic gene delivery is developed and showing high gene deliver

151 Gene delivery is enhanced by the action of targeting and

152 The importance of AAVR for in vivo gene delivery is further highlighted by the robust resis

153 The beneficial effect of Klotho gene delivery is likely due to attenuation of T-cell inf

154 of this new method will aid investigation of gene delivery mechanisms by providing the means to rapid

155 posed limitations include variability in the gene delivery method and a possible point of no return,

156 on in mouse pyramidal neurons using in utero gene delivery methodologies.

157 nrichment in liver tumors after hydrodynamic gene delivery of AKT plasmids.

158 Viral-mediated gene delivery of an activating Gq-DREADD to vmPFC and/or

159 Gene delivery of Ang-(1-9) reduced sudden cardiac death

160 Gene delivery of anti-inflammatory agents to combat the

161 In vivo gene delivery of cardiac reprogramming factors generates

162 ria can be successfully light-sensitized via gene delivery of ChR2.

163 o Adeno-associated virus serotype 9-mediated gene delivery of GJA1-20k to the heart protects Cx43 loc

164 electively immobilize adenoviral vectors for gene delivery of growth factors.

165 after adeno-associated virus (AAV)-mediated gene delivery of mutant human PKP2, which encodes the de

166 Cardiac gene delivery of parvalbumin (Parv), an EF-hand Ca(2+) b

167 the lateral amygdala via lentiviral-mediated gene delivery of RNAi mimicked the behavioral phenotype

168 sion in mice cardiomyocytes by using in vivo gene delivery of specific short hairpin RNAs.

169 We then demonstrated that scaffold-mediated gene delivery of transforming growth factor beta3 (TGF-b

170 he fields of sensors, site-specific drug and gene delivery or protein stabilization attest for the ma

171 escence/nmr), imaging combined with drug and gene delivery, or imaging combined with therapy or diagn

172 Beyond their use in drug/gene delivery, phototherapy, and bioimaging, recent stud

173 The aim of this study was to validate a gene delivery platform based on ultrasound-activated lip

174 ficant extension in the development of novel gene delivery platforms.

175 Understanding the successes and failures of gene delivery polymers and structures is the key to engi

176 rexpression of the Nrg4 gene by hydrodynamic gene delivery prevents HFD-induced weight gain and fatty

177 the development of more efficient AAV-based gene delivery procedures.

178 Non-viral drug and gene delivery protocell platforms offer potential flexib

179 do not regenerate and current stem cell and gene delivery protocols result only in immature HC-like

180 n the OFC by adeno-associated virus-mediated gene delivery reversed a cognitive deficit induced by ch

181 at many genetically-based diseases, however, gene delivery safety and efficacy remains a challenging

182 component was chosen to design and engineer gene delivery separately in a complimentary and fundamen

183 cificity of TALENs with efficient lentiviral gene delivery should advance genome editing in vitro and

184 models and clinical trials; however, current gene delivery strategies are limited to the introduction

185 Current gene delivery strategies routinely use cDNA-based vector

186 tential therapeutic use of miRNA-facilitated gene delivery strategies to heal vessel wall injury.

187 Despite these advantages, gene-delivery strategies using nonviral vectors have poo

188 ansposon system is a highly active non-viral gene delivery system capable of integrating defined DNA

189 utility of the adeno-associated virus (AAV) gene delivery system has been validated by the regulator

190 The adeno-associated virus (AAV) vector gene delivery system has shown promise in several clinic

191 ropylenimine dendrimer is a highly promising gene delivery system to the brain.

192 transduction efficacy of a lentivirus based gene delivery system was not augmented.

193 stimuli triggered, photothermal controllable gene delivery system, which can be further applied to ma

194 ovirions (HPV-PsVs) approach is an effective gene-delivery system that can prime or boost an immune r

195 seases, is currently hampered by the lack of gene delivery systems able to cross the blood-brain barr

196 biodistribution and metabolism of non-viral gene delivery systems administered systemically are dire

197 to be successful, the development of proper gene delivery systems and hypoxia-regulated gene express

198 Non-viral gene delivery systems are one of the most potential alte

199 herapy, and allow for the development of new gene delivery systems based on in vitro-generated papill

200 n made to exploit cardioprotective drugs and gene delivery systems for myocardial infarction (MI).

201 s have been prepared, and their potential as gene delivery systems has been evaluated in comparison w

202 posomal, PEI, dendrimer, stem cell and viral gene delivery systems in order to determine the techniqu

203 Synthetic nanoparticle-based gene delivery systems offer highly tunable platforms for

204 Self-assembled synthetic gene delivery systems represent the bottom-up approach t

205 ry and balance function is likely to require gene delivery systems that target auditory and vestibula

206 racterization of different nanosized drug or gene delivery systems, e.g., polymers, nanoparticles, mi

207 execution of inhaled gene therapy, including gene delivery systems, primary physiological barriers an

208 a new transfection multiplier for non-viral gene delivery systems.

209 systemically delivered nanoparticle nonviral gene delivery systems.

210 use lungs, superior to several gold standard gene delivery systems.

211 report on an optimization of the ultrasound gene delivery technique.

212 discovered and mimicked to improve non-viral gene delivery techniques.

213 en successfully applied to improve non-viral gene delivery techniques.

214 human disease and to progressively improving gene delivery technologies.

215 avenues towards improving the transition of gene-delivery technologies from in vitro assessment to h

216 However, improvements in gene delivery technology mean that gene therapy has the

217 MCM-based transfection is an advancement in gene delivery technology, as it represents a non-viral a

218 In gene delivery the genetic material has to escape from th

219 Instead of viral-mediated therapeutic gene delivery, the authors induced expression of an inte

220 ot noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is

221 -ZN-NIMs and their potential to improve oral gene delivery through improved protection and controlled

222 he envelope pseudotype while scAAV9 mediates gene delivery to 40% of spinal cord motor neurons, with

223 Our results support the potential for gene delivery to BCs and gene replacement therapy in hum

224 id, has been shown to be highly efficient in gene delivery to human airway epithelia.

225 or the first time, the feasibility of 2bF8LV gene delivery to human hematopoietic stem cells to intro

226 Overall, the results demonstrate that using gene delivery to modulate neuroactive steroids shows pro

227 ctors are incapable of efficient or specific gene delivery to NSCs in vivo.

228 almost exclusively employ viral vectors for gene delivery to NSCs though safety and scalability pose

229 AV vectors into pSi microparticles increases gene delivery to otherwise non-permissive endothelial ce

230 cy, it still remains challenging for precise gene delivery to overcome nonspecific adsorption and off

231 g in cocaine seeking, we used viral-mediated gene delivery to overexpress ADAR2b in the accumbens she

232 Gene delivery to primary human cells is a technology of

233 data demonstrate for the first time targeted gene delivery to specialized ECs upon systemic vector ad

234 treatment opportunity based upon successful gene delivery to specific immune cell modulators.

235 In conclusion, AAV1 vectors are suitable for gene delivery to TG sensory neurons following intraderma

236 sound is therefore a viable way of enhancing gene delivery to the brain and merits further research.

237 ighly promising delivery system for systemic gene delivery to the brain.

238 rventions in human cells, including targeted gene delivery to the CCR5 and AAVS1 loci.

239 retofore precluded investigation of systemic gene delivery to the cochlea.

240 Nonviral gene delivery to the liver has been under evolution for

241 AAV has emerged as the vector of choice for gene delivery to the retina, with attention focused on d

242 ng could be modulated in skeletal muscle via gene delivery to the target tissue, thereby avoiding the

243 ted adeno-associated virus (AAV) vectors for gene delivery to the TG after intradermal whiskerpad del

244 s previously undescribed routes for drug and gene delivery to treat other diseases of the central ner

245 dy provide an important advance in improving gene delivery to treat patients with muscular dystrophy.

246 Exo-AAV2 serves as a robust gene delivery tool for murine retina, and the simplicity

247 decade, AAV vectors have emerged as leading gene delivery tools for therapeutic applications and bio

248 ent lentiviral vectors (IDLVs) are promising gene delivery tools that retain the high transduction ef

249 n essential option in the array of available gene delivery tools.

250 the QD fluorescence is combined with drug or gene delivery towards theranostic approaches or with com

251 Unfortunately, current methods of gene delivery treat only a fraction of diseased cells, y

252 Gene delivery using a lentiviral vector leads to efficie

253 t the development and assessment of a hybrid gene delivery vector containing biological and biomateri

254 ese results suggest that AAVrh10 is a useful gene delivery vector to target the sensory nerves innerv

255 otably, this biodegradable end-modified PBAE gene delivery vector was not cytotoxic and maintained th

256 y(ethylenimine) (PEI) 25 kDa is an efficient gene delivery vector with outstanding gene condensation

257 V), which is being developed as an antitumor gene delivery vector, has been determined for wild-type

258 As a unique non-viral gene delivery vector, SSANs outperform commercial transf

259 ated viruses (AAV) are promising therapeutic gene delivery vectors and better understanding of their

260 Viral and non-viral gene delivery vectors are in development for human gene

261 Unfortunately, most gene delivery vectors are incapable of efficient or spec

262 Gene delivery vectors based on adeno-associated virus (A

263 ly poly(ethylene imine) (PEI), are promising gene delivery vectors due to their inherent ability to c

264 pment of peptide vaccines, and generation of gene delivery vectors for cystic fibrosis given the stri

265 Current viral gene delivery vectors for gene therapy are inefficient d

266 The synthetic component of hybrid gene delivery vectors plays a significant role in their

267 the germ line of wasps but also function as gene delivery vectors that wasps rely upon to geneticall

268 (PAEs) have emerged as a promising class of gene delivery vectors with performances that can even be

269 viruses (AAVs), which are being developed as gene delivery vectors, display differential cell surface

270 The inadequacy of gene delivery vectors, including poor intracellular deli

271 n addition to enhancing MNP functionality as gene delivery vectors, minicircle technology provides ke

272 rther development of this promising class of gene delivery vectors, we have investigated their mechan

273 ational design of tumor-targeted recombinant gene delivery vectors.

274 y for the development of optimized non-viral gene delivery vectors.

275 The design of a non-viral gene delivery vehicle capable of delivering and releasin

276 pecially appealing class of biomaterials for gene delivery vehicles as they can be introduced into th

277 Viral vectors, in particular, are powerful gene delivery vehicles for the nervous system, but all a

278 he advantageous characteristics of non-viral gene delivery vehicles to complement the viral vectors.

279 Despite their promise as gene delivery vehicles, a better understanding of the bi

280 When coupled with our previously reported gene delivery vehicles, the slightly cationic microbubbl

281 y parameter for the design of more efficient gene delivery vehicles.

282 es in bionanotechnology, as drug-delivery or gene-delivery vehicles, as nanoreactors or as templates

283 SC gene therapy is the limited efficiency of gene delivery via lentiviral vectors (LVs) into HSCs.

284 Controllable gene delivery via vector-based systems remains a formida

285 In particular, the enhancement of gene delivery was approximately 50 to 100 times better w

286 Chondrogenesis induced by scaffold-mediated gene delivery was as effective as traditional differenti

287 Global gene delivery was demonstrated in dystrophic mice more t

288 photochemical internalization (PCI) mediated gene delivery was evaluated in vitro using the HCT116/LU

289 in vivo model, the safety of the adenoviral gene delivery was evaluated.

290 Moreover, GalphasXL gene delivery was found to be capable of inducing hypert

291 Adenoviral gene delivery was shown to be safe, with no detrimental

292 in mind, adeno-associated virus (AAV) vector gene delivery was used to localize IL-2 expression to th

293 By viral gene delivery, we downregulated mTORC2 solely in the dor

294 The effects of such dual gene delivery were compared with the effects of similar

295 ned and synthesized, and their properties in gene delivery were evaluated in vitro with an aim of dev

296 stry to address barriers associated with APC gene delivery, which include cellular uptake and interna

297 WT hAIPL1 by adeno-associated virus-mediated gene delivery, which was stable up to 6 months after tre

298 the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month

299 re promising vectors for in vivo therapeutic gene delivery, with more than 20 years of intense resear

300 pinal cord, and has the potential to promote gene delivery within the spinal cord, which can influenc